Despite high-profile failures, including the recent disappointing results for Axovant Science’s Phase III MINDSET study, the trial landscape for Alzheimer’s disease remains busy.
Outside the oncology research that dominates pharma R&D, Alzheimer's disease (AD) is one of the more active indications according to Trialtrove. Undeterred by previous failures, the industry continues to mine them for insight, incorporating new strategies and tools in an attempt to address the unmet needs in within the large AD market.
As of October 2017, a total of 240 Phase I to III trials were ongoing for AD – 78% of...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.
The drugmaker announced topline results from the Phase III INDEPENDENCE trial, which did meet key secondary endpoints.
